Mary Wertz

Mary Wertz, Ph.D., is a Senior Scientist at Fulcrum Therapeutics since January 2020, previously holding a position as a Scientist within the same company. With significant postdoctoral experience, Mary Wertz worked at the Broad Institute from January 2016 to January 2020, focusing on genetic modifiers of mutant Huntingtin toxicity using innovative screening techniques. Prior postdoctoral work at Boston Children's Hospital involved the characterization of microRNA and mRNA expression in Spinal Muscular Atrophy, culminating in a published article. The academic background includes a Ph.D. in Neuroscience from Harvard University, where Mary Wertz researched microRNA dysregulation in motor neuron models and developed expertise in molecular profiling. Additional research experience includes roles at Massachusetts General Hospital and Boston College, where early undergraduate research contributed to understanding protein localization and cellular responses.